Akero Therapeutics
Biotechnology ResearchCalifornia, United States51-200 Employees
Akero Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on developing treatments for serious metabolic diseases with high unmet medical need, including MASH. Its lead product candidate, EFX, is being evaluated in the SYMMETRY study, a 96-week Phase 2b trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), and there are three ongoing Phase 3 trials in pre-cirrhotic MASH or compensated cirrhosis: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on two Phase 2b trials, the HARMONY study in pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in compensated cirrhosis due to MASH (F4). The company has 51 to 200 employees and is located at 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080. In October 2025, Novo Nordisk announced plans to acquire Akero Therapeutics for about $4.7 billion in cash. Financial data indicate revenue in the range of $25 million to $50 million and total funding of $367 million.
1-888-653-2347 
support@leadiq.com 
